National Research Council of Canada

Abedelnasser Abulrob

Danica Stanimirovic

Mehdi Arbabi-Ghahroudi

Maria Moreno

Eric Brunette

Nadia Caram-Salas

The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.

Formulations targeting IGFBP7 for diagnosis and therapy of cancer

The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided.

Compositions and methods for brain delivery of analgesic peptides

Anti-ICAM-1 VH single-domain antibodies (sdAbs) are generated by immunizing a llama with recombinant ICAM-1. These antibodies are linked to an imaging moiety for in vivo or ex vivo imaging of ICAM-1-related pathological conditions including atherosclerotic plaques. The antibodies may also be linked to a therapeutic agent to specifically target and treat ICAM-1-related pathological conditions.

Growing community of inventors

Orleans, CA, United States of America

Abedelnasser Abulrob